Shares of Quotient Ltd (NASDAQ:QTNT) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $12.50 for the company and are predicting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Quotient an industry rank of 69 out of 257 based on the ratings given to related companies.

QTNT has been the topic of several analyst reports. ValuEngine upgraded Quotient from a “hold” rating to a “buy” rating in a report on Friday, November 16th. Zacks Investment Research upgraded Quotient from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, BidaskClub upgraded Quotient from a “sell” rating to a “hold” rating in a report on Tuesday, October 2nd.

Hedge funds have recently made changes to their positions in the business. Ardsley Advisory Partners boosted its position in shares of Quotient by 10.0% in the second quarter. Ardsley Advisory Partners now owns 110,000 shares of the company’s stock valued at $883,000 after acquiring an additional 10,000 shares during the period. Trexquant Investment LP bought a new stake in shares of Quotient in the second quarter valued at approximately $102,000. Bank of America Corp DE boosted its position in shares of Quotient by 539.0% in the second quarter. Bank of America Corp DE now owns 16,768 shares of the company’s stock valued at $135,000 after acquiring an additional 14,144 shares during the period. PEAK6 Investments LLC bought a new stake in shares of Quotient in the third quarter valued at approximately $109,000. Finally, Cim Investment Mangement Inc. bought a new stake in shares of Quotient in the second quarter valued at approximately $407,000. Institutional investors own 60.78% of the company’s stock.

QTNT stock traded down $0.33 during midday trading on Friday, hitting $6.64. 1,721,907 shares of the company traded hands, compared to its average volume of 412,233. Quotient has a twelve month low of $2.78 and a twelve month high of $9.02. The company has a market cap of $375.43 million, a PE ratio of -3.29 and a beta of 0.50.

Quotient (NASDAQ:QTNT) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $6.25 million during the quarter, compared to the consensus estimate of $5.80 million. On average, sell-side analysts expect that Quotient will post -1.92 earnings per share for the current fiscal year.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Featured Story: Outstanding Shares

Get a free copy of the Zacks research report on Quotient (QTNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.